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Abstract
Due to recent population emigration movements, an 
epidemic of Chagas disease is currently menacing most 
developed countries. The authors report the case of 
a 53-year-old Brazilian woman living in Europe for the 
last 10 years who developed heart failure symptoms, 
having a previous symptomatic sinus node disease 
with a pacemaker implant at age of 40 years. The di-
agnosis was based on serology and myocardial biopsy 
and the patient was treated with nifurtimox. The au-
thors emphasize the need of a high level of suspicion 
in patients with suggestive epidemiology and the need 
of populational screening of specific high risk groups. 
New treatment options are also discussed.
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INTRODUCTION
Chagas disease (CD) is one of  the parasitic diseases with 
a high economic burden throughout Latin America. It 
affects around 10 million people and has now become 
global due to recent population movements and migra-
tion[1]. Being one of  the 17 neglected tropical diseases, it 
still afflicts the poor and “promotes poverty”. Its pres-
ence outside Latin America is primarily the result of  
migration but it has also been reported among travellers 
and in adopted children. Important transmission routes 
in Europe are transfusion, vertical or organ transplanta-
tion[2]. The challenge in treatment of  chronic CD is due 
to limitations of  the currently available specific treat-
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ments, benznidazole and nifurtimox, and also to the lack 
of  biological markers for the early evaluation of  anti-
parasitic drug efficacy and clinical response[3]. Chronic 
chagasic cardiomyopathy (CCC) is the most serious and 
common etiology of  CCC in Latin America and occurs 
in 20%-30% of  infected subjects, usually 10-30 years af-
ter infection by Trypanosoma cruzi[4].
In this report, we emphasize the implications of  a 
very great latent time until CD diagnosis and emergent 
opportunities in treatment and surveillance programs. 
A brief  presentation of  new therapeutic options is also 
presented at the end of  the paper.
CASE REPORT
In January 2011, a 53-year-old Brazilian woman was re-
ferred for assessment in our Cardiology Clinic and Infec-
tious Diseases Department due to complaints of  heart 
failure and after taking into account her epidemiological 
background.
She had experienced worsening dyspnea with marked 
limitation of  activity and orthopnea for the last 3 mo, 
and was currently graded as class Ⅲ New York Heart 
Association (NYHA). She denied any gastrointestinal 
symptoms or constitutional symptoms.
Her comorbidities were diabetes and hypertension. 
Moreover, in 2002 she was diagnosed with symptomatic 
(syncopal) sinus node disease, presenting with sinus bra-
dycardia of  40 beats/min and frequent sinus pauses and 
non-sustained ventricular tachycardia with runs of  less 
than 5 beats. At that time, echocardiography revealed 
normal left ventricular systolic function and no further 
relevant changes. A DDD-R permanent pacemaker was 
then implanted and some years later she was lost to fol-
low-up. She was currently medicated with metformin/si-
tagliptin, an angiotensin receptor blocker and nitrates. 
She had lived in a rural area in the Goiás state of  
Brazil, located in the central part of  the country, until 
the age of  12 years. Her family house was a typical one 
of  suburban areas in Goiás, with plenty of  palm trees in 
the vicinity. No bed nets were used for protection. She 
had one blood transfusion during her first delivery (age 
24 years). Her mother died when she was 60 years old 
with the diagnosis of  CD. Additionally, she reported two 
sisters and one aunt living in Brazil, also diagnosed with 
CD recently, and her father with the diagnosis of  gastro-
intestinal CD. She had been living in Portugal for the last 
10 years.
On physical examination, a systolic grade Ⅱ/Ⅵ mur-
mur and basal rales were found. Her electrocardiography 
(ECG) revealed atrial pacing and ventricular sensing 
with normal QRS morphology and duration alongside 
frequent ventricular premature beats. On chest X-ray 
cardiomegaly could be easily spotted. Transthoracic 
echocardiogram showed a dilated (59 mm diastolic di-
ameter/1.62 m2 body surface = 36.42 mm/m2) and hy-
pokinetic LV was found. Ejection fraction was estimated 
to be 35% using Simpson method and a grade Ⅱ-Ⅲ
/Ⅳ mitral regurgitation was found (Figure 1). On 24-h 
Holter monitoring, occasional non-sustained ventricular 
tachycardia runs (4 beats) were found. She had a normal 
coronary angiogram and an elevated (28 mmHg) mean 
pulmonary artery pressure was recorded on catheteriza-
tion. Left ventricle (LV) angiogram confirmed a dilated 
LV with generalized hypokinesia, blood stasis and grade 
Ⅲ mitral regurgitation. 
A myocardial biopsy was performed and showed 
plenty of  pseudocysts full of  amastigotes compatible 
with T. cruzi without inflammatory infiltrate (Figure 2). 
Anti-T. cruzi antibodies were detected by the indirect im-
munofluorescent antibody test [IFAT; Trypanosomiasis 
IFA Test System (MarDx)] and by enzyme-linked im-
munosorbent assay [ELISA; Chagatest ELISA Recombi-
nante v.3.0 (Wiener)]. Polymerase chain reaction (PCR) 
for T. cruzi was not performed at this stage.
She was implanted with a cardioversor defibrillator. 
A beta-blocker, warfarin and amiodarone were added to 
her usual medication.
Her two sons (30 and 31 years old, respectively) were 
screened for CD using ELISA and IFAT and they were 
both negative. The patient started antitrypanosomal 
therapy with nifurtimox 10 mg/kg per day, administered 
orally in four divided doses, for 90 d. Side-effects were 
significant: 12 kg weight loss, decreased short-term 
memory, nausea, headache, dizziness and mood changes. 
Despite this, the patient strictly complied with her treat-
ment. Monitoring of  blood count, hepatic enzymes, se-
rum creatinine, and urea was performed before, monthly 
and at end of  treatment. One month after the end of  
treatment anti-T. cruzi antibodies were still detected by 
IFAT and ELISA and PCR for T. cruzi was inconclusive.
No improvement was observed in the patient’s ejec-
tion fraction, which remained stable at 12-mo follow-up. 
She is currently graded as NYHA Ⅱ on regular follow-
up at the Cardiology and Infectious Diseases clinics in 
our hospital. She has been advised not to donate blood 
or organs in the future and not to undergo further preg-
nancies due to the risk of  transmission.
DISCUSSION
In Portugal, CD is an emerging imported parasitosis. 
According to the World Health Organization (WHO) 
Working Group on Chagas disease, there are an esti-
mated 1255 people infected with T. cruzi (prevalence 
rate of  1%) in Portugal, but only 8 cases have been di-
agnosed by laboratory testing[1]. Unfortunately, all these 
cases were lost to follow-up. Our patient is the ninth to 
be diagnosed. This means an index of  underdiagnosis of  
99.4%. The index of  underdiagnosis of  the other eight 
European countries that participated in that surveillance 
study shows that, in general, between 95% and 96% of  
expected cases are not diagnosed[1]. This enormous per-
centage is probably due to illegal immigrants and due to 
the fact of  limited experience in the detection and man-
agement of  CD of  most European health professionals.
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In the Northern Goiás State of  Brazil, where our pa-
tient was born, the presence of  triatomides in dwellings 
or evidence of  triatomide colonization was found to be 
statistically correlated with seropositivity in children[5]. 
Our case report could be a vector-borne transmission 
supported by the very typical correlation with mud hous-
es, such as the one inhabited by our patient during her 
childhood. Less likely, it could have been a blood-borne 
infection due to transfusion. It seems unlikely to be a 
congenital transmission since the mortality rate among 
such infected children is very high, mainly due to acute 
meningoencephalitis and myocarditis, and this transmis-
sion is greatly related to abortion and low-birth weight[6].
The most frequent ECG finding in CD individuals is 
the presence of  right bundle branch block alone or in as-
sociation with left anterior fascicular block. Other ECG 
changes are also frequent, such as atrial and ventricular 
premature beats, intraventricular or atrioventricular con-
duction disturbances, and primary ST-T wave changes[7]. 
Sinus node disease, as an early presentation in a patient 
with no extensive myocardial involvement (and subse-
quent LV systolic function compromise), may suggest 
an abnormality in the innervation of  the sinus node[8]. 
A 10% to 45% prevalence of  sick sinus disease accord-
ing to the level (more prevalent in advanced forms) of  
chagasic cardiomyopathy has been reported[9]. Other 
authors have reported prevalence rates ranging from 
26.8% (in subjects with normal LV systolic function) to 
83.3% in those having compromise[10]. Auto-antibodies 
resulting from a molecular mimicry mechanism may also 
be involved in the pathogenesis of  sick sinus disease[10]. 
Sinus bradycardia and chronotropic incompetence are 
therefore common in these patients. In more advanced 
disease states, marked atrial remodeling and dilatation 
alongside atrial arrhythmias may also occur[11]. 
Congestive heart failure and sudden cardiac death are 
the main causes of  death among chagasic patients. The 
average prevalence of  malignant arrhythmias in these 
patients is unknown, but risk factors have been identi-
fied: regional contractile abnormalities and mild left ven-
tricle dysfunction[12], apical lesions[13], moderate or severe 
LV systolic dysfunction[14], exercise-induced ventricular 
arrhythmia[15], non-sustained ventricular arrhythmia[16], 
New York Heart Association functional class Ⅲ-Ⅳ and 
absence of  β-blocker treatment[17].
According to the Ⅰ Latin American guidelines for 
the diagnosis and treatment of  Chagas cardiomyopa-
thy[18], the patient’s drug therapy would have the follow-
ing classes of  recommendation and levels of  evidence: 
angiotensin receptor blocker (I-C); β-blocker, oral anti-
coagulants (I-C); amiodarone (I-B); and nitrate (Ⅱa-C). 
Further therapy can be introduced in the future if  the 
patient develops congestive symptoms and deteriorates 
into Ⅲ or Ⅳ NYHA class: spironolactone (I-B); diuretic 
(I-C) for congestive symptoms; and digitalis (Ⅱa-C). 
Digitalis, angiotensin-converting enzyme inhibitors[19] 
and beta-blockers[20] have proven to be useful in reduc-
ing neurohormonal activation in patients with advanced 
Chagas cardiomyopathy.
The implantable cardiac defibrillator (ICD) has proven 
to be effective in terminating life-threatening arrhythmias, 
in a registry including mostly patients under secondary 
prevention[21]. These patients have a very high incidence 
of  electrical storms, reaching 15.7% in an ICD registry[21].
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Figure 1  Transthoracic echocardio-
gram: apical 4-chamber view (A), 
parasternal long-axis (B); and (C) 
left ventricle angiogram showing a 
dilated and aneurysmatic left ventri-
cle (36.37 mm/m2 end diastolic and 
31.44 mm/m2 end systolic diameter) 








Figure 2  T. cruzi pseudocyst (ar-
row). A: Heart muscle, Giemsa stain-
ing, 100×; B: Heart muscle, hematoxy-
lin-eosin staining, 100×.
Cortez J et al . Chagas disease
Patients should be selected for this type of  therapy 
according to the international guidelines[22]. However, 
some authors propose that patients with non-sustained 
ventricular arrhythmia without straight indication for 
ICD should be referred for programmed ventricular 
stimulation[23]. Radiofrequency ablation is another option 
for treating these patients, but sometimes an epicardial 
approach may be necessary in order to more effectively 
target the arrhythmia substrate[24].
According to the scoring system defined by Rassi et 
al[25], this patient would be assigned 15 points based on: 
NYHA Ⅲ class (5 points), cardiomegaly on chest X-ray 
(5 points), LV systolic dysfunction on echocardiography 
(3 points) and non-sustained ventricular tachycardia on 
24-h Holter monitoring (2 points). This score puts her in 
the high-risk category (risk of  death in the next 10 years 
of  84%).
PCR for T. cruzi was not performed initially because 
serology is the gold-standard for diagnosis of  chronic 
CD[26,27], despite being affected by cross-reactions with 
antibodies induced by other parasites, namely Leishmania 
and T. rangeli[28]. Due to this, two different serologic tests 
were performed to confirm the results. PCR is used for 
post-treatment follow-up to look for failure of  therapy 
in achieving parasitological response, but its variability in 
sensitivity may be explained by the intermittent presence 
and quantity of  circulating parasites at the time of  blood 
collection[29].
Our patient was not cured as antibody titres did 
not decrease significantly and did not become negative. 
However, this result is often not observed until 8 to 10 
years post-treatment and then only in approximately 
15% of  treated adult subjects[27]. The main impact of  
the great latent time until the diagnosis of  CCC is the 
lack of  efficacy of  the two approved drugs for anti-
trypanosomal therapy in chronically-infected patients. 
Conversely, in acute disease the cure rate is reported to 
be around 85%[30] and in congenital transmission it can 
reach 100%[6]. It is clear that efficacy declines markedly 
with the duration of  infection[3]. Uncertainty remains 
regarding the degree of  efficacy, mainly because of  the 
lack of  a reliable test of  cure, as explained above.
The reason why this patient was treated with nifurti-
mox was due to WHO stock shortage of  benznidazole, 
which seems to be a better tolerated drug[30]. The Benz-
nidazole Evaluation for Interrupting Trypanosomiasis, 
a large, multicenter, double-blind, randomized, placebo-
controlled trial of  benznidazole for patients with mild-
to-moderate CCC, is ongoing and the results will not 
be known until end of  2012[31]. Despite most physicians 
often being reluctant to treat patients with CCC who are 
above 50 years of  age because of  the frequent side ef-
fects, the inability to confirm cure conclusively, and lack 
of  efficacy of  the two currently available drugs, some 
authors have shown a reduction in the rate of  progres-
sion toward advanced cardiopathy compared to un-
treated patients[3,4,30,31]. It is obvious that new treatments 
are urgently needed, and the antifungal triazoles, namely 
posaconazole, have demonstrated potential for therapeu-
tic switching[3,30,32]. Unfortunately, only one clinical case 
has been published of  a previous treatment failure with 
benznidazole and subsequent successful treatment with 
posaconazole using PCR as follow-up[3].  
In the face of  relative unsuitability of  Chagas pa-
tients for heart transplant due to the risks of  increased 
parasitemia when under immunosuppression, the possi-
bility of  using stem cells to treat chagasic cardiomyopa-
thy has been viewed with enthusiasm[33].
In 2004, Soares et al[34] demonstrated that intravenous 
injection of  bone marrow cells into chronic chagasic 
mice resulted in migration to the heart and a signifi-
cant reduction in inflammatory infiltrates and intersti-
tial fibrosis. Guarita-Souza et al[35] have administered 
autologous skeletal myoblasts and mesenchymal stem 
cells from bone marrow to Wistar rats and observed 
a significant improvement in LV ejection fraction and 
reduction in LV end-systolic and end-diastolic function. 
Similar changes were found by another group using 
bone marrow cells in mice[36]. It has been recently pro-
posed that the beneficial immunomodulatory effect of  
this therapy may be related to transcriptomic recovery, 
a measure of  the genes that are either up- or downregu-
lated by the presence of  the disease[37]. The first clinical 
trial was conducted by the group of  Vilas-Boas and col-
leagues in 28 patients using autologous bone marrow 
cells. A significant improvement during an 180-d follow-
up was observed in LV ejection fraction (20.1% ± 6.8% 
to 28.3% ± 7.9%; P < 0.03), NYHA functional class (3.1 
± 0.3 to 1.8 ± 0.5; P < 0.001), Minnesota quality of  life 
questionnaire (50.9 ± 11.7 to 25.1 ± 15.9; P < 0.001) and 
6-min walk test[38]. Nevertheless, a larger randomized, 
double-blind, placebo-controlled clinical trial is needed.
Chagas disease is associated with heart failure, the 
presence of  left ventricular apical aneurysm, left atrial 
dysfunction, cardiac arrhythmias, a proinflammatory 
status and several other factors that predispose to 
stroke[39,40]. Furthermore, the presence of  Chagas disease 
is in itself  an independent risk factor for stroke[41]. The 
possible existence of  a prothrombotic disease state is 
still controversial[42,43]. Sometimes, stroke can be the first 
sign of  Chagas disease in asymptomatic patients or in 
those with mild systolic dysfunction[44]. Recurrence is 
estimated to be around 20%, so secondary prevention 
is recommended[39]. No randomized studies have been 
conducted so far regarding the role of  anticoagulation 
for primary prevention of  thromboembolism in Chagas 
disease. However, Sousa et al[45] have developed a car-
dioembolic risk score including 4 variables: systolic dys-
function (2 points), apical aneurism (1 point), primary 
alteration on ventricular repolarization (1 point) and age 
> 48 years (1 point). According to this score, our patient 
would achieve 4 points, placing her under a risk category 
that has an annual stroke rate of  4.4% and therefore has 
benefit from oral anticoagulation. The decision to use 
aspirin or warfarin to prevent thromboembolism in these 
patients remains an open and challenging question[39]. 
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Another interesting issue regarding chagasic therapy 
is the role of  supplementation with selenium (Se), which 
is an essential micronutrient and an antioxidant at the 
cellular level[46]. Data from Souza et al[47] indicate that Se 
treatment prevents right ventricular chamber increase 
and thus can be proposed as an adjuvant therapy for car-
diac alterations already established by T. cruzi infection. 
Moreover, this author had previously demonstrated that 
a Se-deficient diet contributed to an increased suscepti-
bility to this infection in experimental models and higher 
mortality during T. cruzi infection[48], whereas oral Se 
supplementation at low doses alleviated heart damage[49].
The index of  underdiagnosis estimated for eight Eu-
ropean countries with culture and linguistic proximity 
to Latin American countries is a good indicator of  the 
limited epidemiological impact of  CD in the context of  
European health and surveillance systems. Since subjects 
with CD have low economic resources, the pharmaceuti-
cal companies are not particularly interested in supporting 
research and development of  new drugs. Delay in diag-
nosis may result in progression of  cardiac disease. New 
therapeutic options are promising a better future for CD, 
but their efficacy and safety still need to be tested. The 
priority should be the implementation of  screening pro-
grams for target populations (women of  childbearing age 
and a high suspicion level in young patients with heart fail-
ure or dysrhythmias at risk of  having been infected earlier 
in endemic countries) and the training of  professionals in 
the detection of  possible cases, as well as implementation 
of  rigorous protocols for blood and organ donation, are 
essential to limit the impact of  Chagas disease in countries 
where there is no vector transmission.
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